Dr. Gary Fong
- University of California, Los Angeles, Bachelor of Science
University of California, San Francisco, Doctor of Pharmacy
Dr. Fong received his Bachelor of Science degree in Microbiology, Immunology and Molecular Genetics from UCLA in 2010. He went on to receive his Doctor of Pharmacy degree from the UCSF School of Pharmacy in 2014. While at UCSF, he developed an interest in pharmacokinetics and infectious diseases and taught second year students as a teaching assistant in the clinical pharmacokinetics course. After graduation, he completed a pharmacy practice residency at UCSF Medical Center and then moved to Houston, TX to pursue a clinical fellowship in Infectious Diseases at Baylor St. Luke’s Medical Center and the University of Houston College of Pharmacy. Throughout his training, Dr. Fong has been involved with teaching pharmacy and medical trainees in both the classroom and clinical setting. He has also precepted several pharmacy students and residents during his fellowship and has given formal Continuing Pharmacy Education (CPE) and Continuing Medical Education (CME) presentations. He was awarded the Long Excellence in Teaching Award in 2013 for his teaching efforts at UCSF.
During Dr. Fong’s fellowship, he completed both clinical and laboratory research to further elucidate the treatment options and outcomes for patients with invasive fungal infections. Specifically, he has looked at clinical outcomes and resistance patterns of patients with ventricular assist devices who developed candidemia. In the laboratory, he helped create a pharmacokinetic-pharmacodynamic (PKPD) model to simulate different dosing strategies for various antifungals against several different strains of sensitive and resistant Candida spp.
Dr. Fong’s research interests are in the areas of antifungal resistance and PKPD. His research has focused on optimizing current antifungal dosing strategies in normal and non-normal patient populations as well as further understanding the clinical impact and management of emerging echinocandin resistance in patients with invasive candidiasis. He is also interested in bacterial resistance patterns and improving the application of clinical pharmacokinetics in the acute care setting. His educational interests include active learning integration, case-based teaching and use of innovative technology to improve student education. While Dr. Fong has performed several laboratory experiments during his fellowship training, he ultimately plans to focus his research efforts on clinical outcomes and educational improvement.
Recent Creative, Scholarly Work and Publications
Hu C, Fong G, Wurster S, Kontoyiannis DP, Beyda ND. Clumping morphology influences virulence uncouple from echinocandin resistance in Candida glabrata. Microbiol Spectr. 2022;10(1):e0183721.
Fong G, Chahine EB, Justo J, Narayanan N, et al. Assessment of antimicrobial pharmacokinetics curricula across schools and colleges of pharmacy in the United States. J Am College Clin Pharm. 2021;5(1):58-66.
Lee BV, Fong G, Bolaris M, Neely M, et al. Cost-benefit analysis comparing trough, two-level, AUC and Bayesian AUC dosing for vancomycin. Clin Microbiol Infect. 2020; doi: 10.1016/j.cmi.2020.11.008. Online ahead of print.
Gregorian T, Alvarez N, Fong G, Xavioer S, Goad J. Preventing the Herpes Zoster Virus via Vaccination: The Role of the Retail Pharmacist as Patient Advocate, Identifier, Educator and Immunizer. Pharmacy Times. August 2018; 74-85
Vitt JR, Do LV, Shah NR, Fong G, et al. A before-after study of an electronic order set for reversal of vitamin K antagonist-associated intracerebral hemorrhage. Neurohospitalist. 2018 Jan;8(1):18-23.
Fong G, Skoglund EW, Phe K, et al. Significant Publications on Infectious Diseases Pharmacotherapy in 2016. J Pharm Pract. 2017. Advance onlne publication. doi: 10.1177/0897190017727212.
Corelli RL, Muchnik MA, Beechinor RJ, Fong G, Vogt EM, Cocohoba JM, Tsourounis C, Hudmon KS. Perceptions and cost-analysis of a multiple mini-interview in a pharmacy school admissions process. Am J Pharm Educ. 2015;79(9):135.